Guofu Chen1,2, Liming Sheng3,4, Xianghui Du5,6. 1. Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. 2. Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China. 3. Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. m05shengliming@126.com. 4. Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China. m05shengliming@126.com. 5. Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. duxianghui88@aliyun.com. 6. Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Cancer Hospital, 1 Banshandong Road, Hangzhou, 310022, Zhejiang, China. duxianghui88@aliyun.com.
Abstract
OBJECTIVE: The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS: The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent chemoradiotherapy were collected and reviewed. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software. RESULT: The efficacy of treatment was classified as complete remission in 4 cases (10.5%), partial remission in 22 cases (57.9%) and stable disease in 12 cases (31.6%). The objective response rate was 68.4% (26/38). The most common types of hematological toxicities were anemia (65.7%) and leukopenia (57.9%), but all the events were transient. No paclitaxel-induced allergic reactions occurred during the treatment. The median PFS and OS time were 17.0 and 29.0 months. CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy showed a significant antitumor effect to LSCC with manageable toxicities. Further clinical investigation are warranted to evaluate the efficacy of this regimen.
OBJECTIVE: The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS: The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent chemoradiotherapy were collected and reviewed. The overall response, toxicities, progression-free survival and overall survival were analyzed with SPSS software. RESULT: The efficacy of treatment was classified as complete remission in 4 cases (10.5%), partial remission in 22 cases (57.9%) and stable disease in 12 cases (31.6%). The objective response rate was 68.4% (26/38). The most common types of hematological toxicities were anemia (65.7%) and leukopenia (57.9%), but all the events were transient. No paclitaxel-induced allergic reactions occurred during the treatment. The median PFS and OS time were 17.0 and 29.0 months. CONCLUSIONS: Liposome-paclitaxel and carboplatin concurrent with radiotherapy showed a significant antitumor effect to LSCC with manageable toxicities. Further clinical investigation are warranted to evaluate the efficacy of this regimen.
Authors: Guo-Rao Wu; Min Zhou; Yi Wang; Qing Zhou; Lei Zhang; Long He; Shu Zhang; Qilin Yu; Yongjian Xu; Jianping Zhao; Weining Xiong; Cong-Yi Wang Journal: Front Immunol Date: 2022-08-25 Impact factor: 8.786